TICKERNOMICS Sign up
Last Update: 2024-03-28 02:13:52
Stereotaxis Inc. ( STXS ) https://www.stereotaxis.com
2.49USD
Sector:
Healthcare
Industry:
Medical Instruments & Supplies
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
STXS
30.37%
SPY
32.74%
-64.02%
STXS
SPY
92.93%
STXS
27.69%
SPY
224.41%
-38.21%
STXS
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
207.00
192.45
0.15
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-10.65
7.02
9.44
-9.65
0.00
-8.92
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-72.30
52.05
-71.87
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.492
-140.42
-66.55
1.40
Other Earnings and Cash Flow Stats:
Stereotaxis Inc. ( STXS ) Net Income TTM ($MM) is -19.26
Stereotaxis Inc. ( STXS ) Operating Income TTM ($MM) is -20.77
Stereotaxis Inc. ( STXS ) Owners' Earnings Annual ($MM) is -11.30
Stereotaxis Inc. ( STXS ) Current Price to Owners' Earnings ratio is -12.77
Stereotaxis Inc. ( STXS ) EBITDA TTM ($MM) is -20.19
Stereotaxis Inc. ( STXS ) EBITDA Margin is -71.87%
Capital Allocation:
Stereotaxis Inc. ( STXS ) has paid 0.00 dividends per share and bought back -6.407788 million shares in the past 12 months
Stereotaxis Inc. ( STXS ) has reduced its debt by 0.371 million USD in the last 12 months
Capital Structure:
Stereotaxis Inc. ( STXS ) Interest-bearing Debt ($MM) as of last quarter is 5
Stereotaxis Inc. ( STXS ) Annual Working Capital Investments ($MM) are 2
Stereotaxis Inc. ( STXS ) Book Value ($MM) as of last quarter is 21
Stereotaxis Inc. ( STXS ) Debt/Capital as of last quarter is 33%
Other Balance Sheet Stats:
Stereotaxis Inc. ( STXS ) has 19 million in cash on hand as of last quarter
Stereotaxis Inc. ( STXS ) has 13 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Stereotaxis Inc. ( STXS ) has 82 common shares outstanding as of last quarter
Stereotaxis Inc. ( STXS ) has 0 million USD of preferred stock value
Academic Scores:
Stereotaxis Inc. ( STXS ) Altman Z-Score is -12.21 as of last quarter
Stereotaxis Inc. ( STXS ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Stereotaxis Inc. ( STXS ) largest shareholder is owning shares at 0.00 ($MM) value
Menawat Arun Swarup(an insider) Bought 10449 shares of Stereotaxis Inc. ( STXS ) for the amount of $0.00 on 2022-01-04
15.02% of Stereotaxis Inc. ( STXS ) is held by insiders, and 44.57% is held by institutions
Stereotaxis Inc. ( STXS ) went public on 2004-08-12
Other Stereotaxis Inc. ( STXS ) financial metrics:
FCF:-10.36
Unlevered Free Cash Flow:-12.44
EPS:-0.28
Operating Margin:-72.30
Gross Profit Margin:52.05
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-139.68
Beta:1.40
Buffet's Owners Earnings:-11.30
Price to Owner's Earnings:-12.77
About Stereotaxis Inc. ( STXS ) :
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.